Physician profile
Lloyd J Cleaver
NPI 1104829829
$14,260.69
in general payments reported to CMS, 2019-2025
43 companies · $2,346 in 2025
The $2,346 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $533 · 2021: $2,369 · 2022: $2,078 · 2023: $2,712 · 2024: $3,298 · 2025: $2,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,842 · Education: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,842.18 |
| Education | $514.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,972.86 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Horizon Therapeutics Plc | $1,053.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $1,051.92 | 2019-2025 | Ilumya, Blu-U, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $1,013.82 | 2022-2025 | Sotyktu |
| Amgen INC. | $980.53 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $786.95 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $674.44 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $668.20 | 2020-2025 | Tremfya |
| Ucb, INC. | $608.25 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $597.63 | 2019-2025 | |
| Galderma Laboratories, L.P. | $537.18 | 2021-2025 | Nemluvio |
| Genzyme Corporation | $485.20 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $446.88 | 2024-2025 | Tremfya |
| Pfizer INC. | $433.48 | 2019-2025 | |
| Dermavant Sciences, INC. | $302.92 | 2023-2024 | Vtama |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lloyd Cleaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.